The easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipeline. For some early-stage companies, however, what would otherwise be a useful chart is better referred to as a “hypeline.”

It’s a tongue-in-cheek moniker for the overly braggadocious renderings and descriptions of the drug candidates and therapies a new company hopes to bring to market. A normal pipeline might include just one column for preclinical studies. A “hypeline,” in contrast, will include milestones above and beyond the three traditional phases of clinical trials. Others might conveniently forget to represent later-stage clinical trials, like Inozyme, or find creative ways to represent discovery work, like Mersana did.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy